NVIDIA Boltz-2 NIM Accelerates Drug Discovery

Astellas Pharma has deployed NVIDIA's Boltz-2 NIM AI platform to significantly accelerate drug discovery by enabling experimental scientists to predict biomolecular structures accurately, reducing compound testing by 90% and shortening hit identification time by 70%. The AI model's efficiency has led to widespread adoption within the company, facilitating collaboration between computational and medicinal chemists and advancing structure-based drug design workflows.

This Wire brief sits within Fusion42's coverage of Drug Discovery.